Tromsø, Norway, 26[th] March 2021 - ArcticZymes Technologies ASA (OSE: AZT)
announces it has successfully scaled-up the manufacturing of its SAN HQ enzyme

ArcticZymes TechnologiesŽ Salt Active Nuclease High Quality (SAN HQ) enzyme
offers gene therapy and vaccine customers a more cost effective and technically
superior solution for the removal of contaminating DNA during the manufacturing
process of therapeutic viruses.

The Company entered the therapeutic segment with its SAN portfolio in 2016.
Since then, it has rapidly grown its customer base and subsequent sales. In 2020
the segment accounted for 41% of total sales revenues and demand continues to
grow. As a consequence, there was a need to transition from small-scale
fermentation production into significantly larger-scale fermenters so that
customers can receive large quantities of enzyme from a single production batch.
This successful upscaling achieved greater than a 100-fold increase in
fermentation yield and enzyme manufactured from this upscaled process will be
commercially available to our customers from early Q2.

The project was partial funded by a national grant received in May 2020 from
Innovation Norway. We are grateful to Innovation Norway for supporting the
project and recognizing its underlying value.

ArcticZymes Technologies ASA, CEO, Jethro Holter said:

"The upscaling of SAN HQ is core to ensure continuity of supply to our customers
as we mutually grow business together."

For more information, please contact:

ArcticZymes Technologies
CEO, Jethro Holter                           Tel: +47 46 85 91 46
CFO, Børge Sørvoll        Tel: +47 95 29 01 87 ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec]
ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies
in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at
the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents.

For more information, please visit the website: www.arcticzymes.com.